...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: More Exempt Distribution Investments

Mixed: Some Common Shares at 80.5 cents and some at $1.34 (CAN)

 

Koo

 

Share
New Message
Please login to post a reply